Our helpline: 01924 200799 Mon-Fri, 9am-4pm

The MifeMiso trial

The MifeMiso trial is an important research study which is looking at whether a single drug treatment (misoprostol) or a combination of drug treatments (mifepristone plus misoprostol two days later) is best for the medical management of missed miscarriage.

Update at 31 July 2019: Recuitment to the trial has now closed.  We look forward to learning the results in mid-2020.

We provide information about this research trial below, and you can read more about medical management of miscarriage here.

About the MifeMiso trial

MifeMiso is a randomised, double-blind, placebo-controlled trial:

Randomised: The women who have taken part were given either the treatment drug (mifepristone) or a placebo – a dummy drug that has no active ingredients. A computer makes the selection so it’s completely random.

Double-blind: The women in the study were not told whether they were taking the active medicine or the placebo – and neither were their doctors. So both were blinded to this information.

Placebo-controlled: Half the women in the study had the active medicine and half (the controls) had the placebo.  The medicine that they received looked exactly the same to them and their doctors, but a completely separate group kept a record of which women had mifepristone and which had the placebo.

It is important to note that all women received misoprostol two days later, which is currently the recommended treatment for the medical management of miscarriage.

Recruitment to the MifeMiso trial is now closed but here is the information that we provided while it was open:

Who can take part?

The researchers are recruiting women who:

What would I need to do?

If you agree to take part, you will be given the first tablet to take by mouth whilst you are at the hospital. Two days later, you will be asked to take the second tablet. How you take this depends on your local hospital; it might involve you coming back to the hospital to insert the tablet into your vagina (rather like using a tampon) or you may take it by mouth. You would then need to come back to the hospital five days later for a check-up scan to see if your miscarriage is now resolved.

The trial team will collect most of their study information from your hospital notes but they may need to contact you to check some details. They will ask you to complete a short questionnaire to record how you are feeling at your hospital visits and upon discharge.

Once your miscarriage has resolved, you will also be asked to complete a questionnaire to record your experiences of taking part in the trial. With your permission, you may be asked to talk in depth with one of the dedicated research team members to provide a more in depth description of your experiences.

Where is it taking place?

 The trial will recruit women from centres across England, Scotland and Wales. The following hospitals are currently recruiting patients:

We’ll add new sites to the list as they open.

A personal experience

Emma took part in the MifeMiso trial.

After having two healthy pregnancies, I was shocked and very distressed to find at my 12 week scan that my third pregnancy had not progressed beyond six weeks – a missed miscarriage.

As I had not naturally miscarried the baby in the 6 weeks since the pregnancy ended, and surgery seemed so invasive, I decided [on] the medical option and chose to take part in the MifeMiso research trial.  This way I could contribute to scientific knowledge and something good would come out of this experience.

She shares her experience here.

More information

If you would like more information, or have questions or concerns about the trial, please contact the MifeMiso trial office at mifemiso@trials.bham.ac.uk. You may also like to visit the trial website.

If your questions are less medical/scientific and more about feelings or concerns, do contact us at info@miscarriageassociation.org.uk or call us on 01924 200799.

 

This study is funded by the NIHR HTA (project reference 15/160/02).

The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.